Silence Therapeutics Plc ( (SLN) ) has released its Q4 earnings. Here is a breakdown of the information Silence Therapeutics Plc presented to its investors.
Silence Therapeutics Plc is a global clinical-stage biotechnology company focused on developing novel siRNA therapies to silence disease-causing genes, primarily targeting the liver and addressing unmet medical needs in cardiovascular, hematology, and rare diseases.
In its latest earnings report for the year ending December 31, 2024, Silence Therapeutics highlighted significant clinical progress and pipeline advancements, particularly with its mRNAi GOLD™ platform. The company reported a strategic focus on rare conditions with unmet needs, such as the ongoing development of divesiran for polycythemia vera (PV) and plans for a Phase 3 study of zerlasiran for cardiovascular disease, contingent on securing a partner.
Financially, Silence ended 2024 with $147.3 million in cash and equivalents, extending its cash runway into 2027. The company saw a notable increase in collaboration revenue to $43.1 million, up from $30.9 million in 2023, driven by the completion of obligations under collaboration agreements. R&D expenses rose to $67.9 million due to increased clinical activities, while the net loss narrowed to $45.3 million from $54.2 million in the previous year.
Silence Therapeutics remains committed to advancing its pipeline, with plans to fully enroll the SANRECO Phase 2 study of divesiran by the end of 2025 and ongoing discussions to partner for the zerlasiran Phase 3 study. The company also plans to initiate a Phase 1 study of SLN548 in 2025 and continues its collaboration with AstraZeneca on SLN312.
Looking ahead, Silence Therapeutics aims to leverage its extended cash runway to invest in its innovative pipeline, focusing on delivering first-in-class siRNA therapies for rare diseases and continuing its strategic partnerships to support further clinical developments.